Gurugram-based healthcare startup Oncare has successfully secured $4 million in a Series A funding round led by Sky Impact Capital. The company, which operates specialized oncology departments within existing mid-sized hospitals, aims to make cancer treatment more affordable and accessible across India. This new capital injection is earmarked for significant geographic expansion and technological enhancements to further its mission of democratizing quality cancer care.
A Capital-Efficient Approach to Oncology
Oncare addresses the high cost of healthcare infrastructure by embedding its services within accredited partner hospitals rather than building new facilities. This capital-efficient, hospital-in-hospital model allows for rapid scaling without the extensive financial outlay typically associated with medical expansion. The platform integrates medical, surgical, and radiation oncology services, ensuring comprehensive care under a standardized clinical governance framework.
A key pillar of Oncare's value proposition is its ability to drastically reduce treatment costs for patients. The company claims to offer chemotherapy at prices approximately 40% lower than corporate hospitals by leveraging pooled procurement for high-cost medicines. This centralized purchasing power overcomes the limited bargaining ability of individual mid-sized hospitals, directly translating into significant savings for families.
Strategic Expansion to Address Healthcare Gaps
With the fresh infusion of capital, Oncare is set to embark on an ambitious expansion plan beyond its current base in Delhi-NCR. The company will establish a presence in the metro city of Bangalore while also targeting underserved Tier-2 and Tier-3 cities. Key focus areas include regions in Uttar Pradesh, Bihar, and West Bengal, where there is a significant demand-supply gap for specialized care.
This strategic expansion directly confronts the geographic disparity in India's healthcare system, where specialized oncology services are clustered in major urban centers. By bringing advanced cancer treatment closer to patients' homes, Oncare aims to reduce the significant financial and emotional burden of travel and accommodation. This model could serve as a blueprint for delivering other complex medical services in non-metropolitan areas across the country.
Investor Confidence and Market Potential
The funding round, which also saw participation from Huddle Ventures, Lotus Herbal Group, and others, signals strong investor confidence in Oncare's disruptive model. Aakash Sachdev, Founder of Sky Impact Capital, noted that India's oncology challenge requires scalable operating systems, not just infrastructure, highlighting Oncare's next-generation approach. This investment aligns with Sky's experience in scaling single-specialty healthcare platforms, such as ASG Eye Hospitals.
Oncare is operating within India's rapidly growing oncology care market, which is projected to reach $4.73 billion by FY28. The startup's model is uniquely positioned to capture this growth by addressing the market's core issues of affordability and uneven access. Since its launch in 2023, the company has already demonstrated significant traction, having interacted with around 30,000 patients.
Enhancing Patient Experience Through Technology
Beyond geographic growth, the investment will fuel deeper advancements in Oncare's technology infrastructure to improve the patient journey. The funds will be used to streamline clinical operations, enhance care coordination between different specialists, and create a more transparent treatment process. This focus on technology aims to make the overwhelming experience of a cancer diagnosis more manageable and humane for patients and their families.
This Series A funding marks a pivotal moment for Oncare, empowering it to scale a model that promises both clinical excellence and affordability. By expanding its network of cancer care centers into underserved regions, the company is poised to make a meaningful impact on India's healthcare landscape. The investment validates a vision to redefine cancer care delivery, bringing trusted, high-quality treatment closer to communities nationwide.